Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Ethnopharmacol ; 234: 112-118, 2019 Apr 24.
Article in English | MEDLINE | ID: mdl-30580024

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Zuotai (gTso thal) has a long history in the treatment of cardiovascular disease, liver and bile diseases, spleen and stomach diseases as a precious adjuvant in Tibetan medicine. However, Zuotai is a mercury preparation that contains 54.5% HgS. Its application has always been controversial. AIM OF THE STUDY: To evaluate the toxicological effects of Zuotai in hepatocytes and in zebrafish. MATERIALS AND METHODS: MTT was used to determine the survival rate of hepatocytes; Hoechst and TUNEL staining were used to detect the apoptosis cells; Western blot and RT-qPCR assay were used to determine the expression levels of the protein and mRNA; Liver morphology observation and H&E staining were used to evaluate the hepatotoxicity of Zuotai in Zebfrafish. RESULTS: The survival rate of L-02 cells, HepG2 cells and RBL-2A cells reduced by Zuotai (10-4-0.1 mg/mL) in a dose and time-dependent manner. Zuotai (0.1 mg/mL) induced HepG2 cells shrinkage, condensation and fragmentation and increased the number of apoptosis cells. The protein expression levels of cleaved Caspase-3 and Bax were increased and the expression levels of Bcl-2 were reduced after HepG2 cells exposed to Zuotai (10-4-0.1 mg/mL) for 24 h. In addition, Zuotai (0.2 mg/mL) induced the darker liver color of the larval zebrafish and changed the liver morphologic of adult zebrafish. Zuotai (0.2 mg/mL) also increased the mRNA levels of CYP1A1, CYP1B1 and MT-1 in the liver of adult zebrafish. However, no significantly hepatotoxicity was observed after hepatocytes and zebrafish exposed to HgS at the same dose. CONCLUSIONS: Results showed that Zuotai induced hepatotoxicity effectively under a certain dose but its hepatotoxicity likely occurs via other mechanisms that did not depend on HgS.


Subject(s)
Apoptosis/drug effects , Chemical and Drug Induced Liver Injury/etiology , Hepatocytes/drug effects , Mercury Compounds/toxicity , Animals , Blotting, Western , Cell Survival/drug effects , Chemical and Drug Induced Liver Injury/pathology , Dose-Response Relationship, Drug , Hepatocytes/pathology , Humans , In Situ Nick-End Labeling , Medicine, Tibetan Traditional/adverse effects , Medicine, Tibetan Traditional/methods , Mercury Compounds/administration & dosage , Rats , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , Zebrafish
2.
Br J Haematol ; 125(2): 128-40, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15059134

ABSTRACT

Matrix metalloproteinases (MMPs) are important for the pathogenesis and progression of different tumours. MMPs-2 and -9 are the principal MMPs produced by lymphocytes; these enzymes can degrade a number of matrix proteins but are the two main MMPs that digest type IV collagen, the major component of basement membranes. Therefore, these enzymes are potentially important for tissue invasion and remodelling by malignant lymphocytes. This study showed that chronic lymphocytic leukaemia (CLL) cells produce and secrete variable amounts of pro-MMP-9, but no MMP-2 or tissue inhibitor of metalloproteinase 1 (TIMP-1). The pro-enzyme was found in monomeric and dimeric forms and also complexed with lipocalin. Moreover, a small fraction of secreted monomer became associated with the cell surface and activated upon cell adhesion to insolubilized type IV collagen. High levels of intracellular MMP-9 were associated with advanced (stage C) disease and with poor patient survival. Immunohistochemical studies demonstrated that MMP-9 was associated with areas of tissue invasion and remodelling. The relatively specific MMP-9 inhibitors, Ro31-9790 (3 micromol/l) and TIMP-1, reduced CLL-cell migration through type IV collagen and through endothelial monolayers suggesting that the enzyme may also be important in malignant cell entry and egress to and from involved tissue. Our data raise the possibility that MMP-9 modulation may have therapeutic potential in advanced CLL.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/enzymology , Matrix Metalloproteinase 9/biosynthesis , Blotting, Western , Carrier Proteins/metabolism , Cell Movement , Collagen Type IV/metabolism , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Lipocalins , Matrix Metalloproteinase 9/metabolism , Neoplasm Staging , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...